Skip to main content
Premium Trial:

Request an Annual Quote

Jan Mous

Premium

Jan Mous, former CSO of Lion Bioscience, has been appointed CEO of genomic-based target discovery firm IntegraGen. Mous will also serve as chairman of the company’s board of directors. Mous left his post as CSO of Lion in January, after holding the position for three years. Prior to that, he spent fifteen years at Roche (Basel, Switzerland), where he was global head of genomics technology and managing director of the genetics/genomics technology platform.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.